AMD

Three EURETINA 2026 e-posters examine OCT/OCTA biomarkers and real-world switching to faricimab or aflibercept 8 mg in nAMD.

Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.

Non-invasive electrical stimulation delivered through closed eyelids improved retinal structure and photoreceptor function.

Subretinal deposits are linked to worse surgical risks in patients with severe aortic stenosis and reduced systemic blood flow.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.

Gene therapies, Tie2 agonism, and new delivery platforms are advancing through phase 3 trials in wet and dry AMD, testing mechanisms distinct from anti-VEGF and complement inhibition.

Presenters highlight clinical insights and lessons from recent trial data and surgical experience

New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year, and treatment gaps are linked to worse long-term vision.

A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, including in patients with concurrent neovascular AMD, per Nimesh Patel, MD, at ASRS 2026.

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 dose, outperforming aflibercept 2 mg.

Cascade Prodrug and Uneedle are partnering to test suprachoroidal delivery of CPD100 using Uneedle's Bella-Vue microneedle system for the treatment of wet AMD.

From a phase 3 durability readout for a first-in-class TKI to a new interchangeable ranibizumab biosimilar and a deep dive into geographic atrophy management, June brought a wide-ranging mix of regulatory, clinical, and practice-pattern news for retina specialists

Three cases illustrate how next-generation anti-VEGF agents are extending treatment intervals and improving durability across retinal vascular disease.

SOL-1 results show intravitreal axitinib hydrogel delivered superior vision maintenance and anatomic outcomes through 52 weeks.

Learn how FDA’s interchangeable ranibizumab biosimilar may streamline injections, cut costs, and guide safe switching for retina patients.